Please login to the form below

Not currently logged in
Email:
Password:

RIPK1 inhibitor

This page shows the latest RIPK1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib

Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib

Sanofi’s investigational BTK inhibitor, tolebrutinib, has been shown to have a significant effect on the key central nervous system immune mediators that may drive multiple sclerosis (MS) disease progression, according ... phase 2 MS trial design for

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...